Stent thrombosis relationship to discontinuation of antiplatelet therapy

Jump to navigation Jump to search

WikiDoc Resources for Stent thrombosis relationship to discontinuation of antiplatelet therapy

Articles

Most recent articles on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Most cited articles on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Review articles on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Articles on Stent thrombosis relationship to discontinuation of antiplatelet therapy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Images of Stent thrombosis relationship to discontinuation of antiplatelet therapy

Photos of Stent thrombosis relationship to discontinuation of antiplatelet therapy

Podcasts & MP3s on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Videos on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Evidence Based Medicine

Cochrane Collaboration on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Bandolier on Stent thrombosis relationship to discontinuation of antiplatelet therapy

TRIP on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Clinical Trials

Ongoing Trials on Stent thrombosis relationship to discontinuation of antiplatelet therapy at Clinical Trials.gov

Trial results on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Clinical Trials on Stent thrombosis relationship to discontinuation of antiplatelet therapy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Stent thrombosis relationship to discontinuation of antiplatelet therapy

NICE Guidance on Stent thrombosis relationship to discontinuation of antiplatelet therapy

NHS PRODIGY Guidance

FDA on Stent thrombosis relationship to discontinuation of antiplatelet therapy

CDC on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Books

Books on Stent thrombosis relationship to discontinuation of antiplatelet therapy

News

Stent thrombosis relationship to discontinuation of antiplatelet therapy in the news

Be alerted to news on Stent thrombosis relationship to discontinuation of antiplatelet therapy

News trends on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Commentary

Blogs on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Definitions

Definitions of Stent thrombosis relationship to discontinuation of antiplatelet therapy

Patient Resources / Community

Patient resources on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Discussion groups on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Patient Handouts on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Directions to Hospitals Treating Stent thrombosis relationship to discontinuation of antiplatelet therapy

Risk calculators and risk factors for Stent thrombosis relationship to discontinuation of antiplatelet therapy

Healthcare Provider Resources

Symptoms of Stent thrombosis relationship to discontinuation of antiplatelet therapy

Causes & Risk Factors for Stent thrombosis relationship to discontinuation of antiplatelet therapy

Diagnostic studies for Stent thrombosis relationship to discontinuation of antiplatelet therapy

Treatment of Stent thrombosis relationship to discontinuation of antiplatelet therapy

Continuing Medical Education (CME)

CME Programs on Stent thrombosis relationship to discontinuation of antiplatelet therapy

International

Stent thrombosis relationship to discontinuation of antiplatelet therapy en Espanol

Stent thrombosis relationship to discontinuation of antiplatelet therapy en Francais

Business

Stent thrombosis relationship to discontinuation of antiplatelet therapy in the Marketplace

Patents on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Experimental / Informatics

List of terms related to Stent thrombosis relationship to discontinuation of antiplatelet therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editors-In-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.


Incidence of premature discontinuation of antiplatelet therapy

In a prospective study analyzing 1622 patients who received at least one DES, 14.4% discontinued at least 1 antiplatelet drug, predominantly clopidogrel with an incidence of 11.8% for at least five consecutive days during the first year post-implantation.[1]


Predictors of premature discontinuation of antiplatelet therapy

According to a prospective study analyzing 1622 patients[1], the following observations were made as the reason for discontinuation of one or both antiplatelet therapy:

  • Bleeding events or invasive procedures:
    • Nearly 50% patients had interventions or minor bleeding that did not require discontinuation.
    • In patients who discontinued due to bleeding events/invasive procedures, predictors included renal impairment, prior major hemorrhage, or peripheral artery disease
  • Medical decisions: 32% patients were either undergoing procedures in a private hospital or did not receive instructions in whom medical decision was the cause.
  • Patient decision: 18% patients stopped antiplatelet therapy on their own accord or were on psychotropic drugs.


According to the results evaluated in the PREMIER registry of MI patients[2], predictors of premature thienopyridine discontinuation included:

  • Older age,
  • Lower level of education,
  • Avoidance of healthcare because of cost,
  • Unmarried,
  • Anemia,
  • Preexisting cardiovascular disease,
  • Absence of discharge instructions about the medication, and
  • Lack of referral to a cardiac rehabilitation program.


Risk associated with premature discontinuation of antiplatelet therapy

In patients with DES[3] [4] [2] [5], the most important risk factor for late ST (>30days to 1year) was premature cessation (less than 6 months) of antiplatelet therapy.

Clinical trial data:

  • In a prospective observational cohort study[3] followed for 18 months analyzing 3021 patients, thienopyridine was discontinued during the first six months which was the major determinant of ST(hazard ratio 13.7). However there is insufficient information available on the benefit of continuing thienopyridine beyond 6 months.
  • From a total cohort of 2974 consecutive patients treated with DES[4], 38 patients presented with angiographic evidence of ST. Acute ST occurred in 5 patients, subacute ST in 25 patients and late ST in 8 patients. Individuals who discontinued clopidogrel more likely had late ST (36.8% versus 10.7% percent in those without stent thrombosis). The mean duration between cessation of clopidogrel and stent thrombosis was 153 days.
  • In the aggregate the above studies suggest that thienopyridine therapy for at least six months, in addition to aspirin, reduces the likelihood of ST during the first year after DES placement. However, these studies do not inform us as to the optimal time to stop thienopyridine. It is possible that the benefit of dual antiplatelet therapy, particularly considering the bleeding risk, may become small after six months. In the absence of better evidence, however, we recommend dual antiplatelet therapy for at least one year after DES.


Risk associated with late discontinuation of antiplatelet therapy

Duration of dual antiplatelet therapy

Failure of therapy

Preventing premature discontinuation of antiplatelet therapy

References

  1. 1.0 1.1 Ferreira-González I, Marsal JR, Ribera A, Permanyer-Miralda G, García-Del Blanco B, Martí G; et al. (2010). "Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation". Circulation. 122 (10): 1017–25. doi:10.1161/CIRCULATIONAHA.110.938290. PMID 20733100.
  2. 2.0 2.1 2.2 Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS; et al. (2006). "Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry". Circulation. 113 (24): 2803–9. doi:10.1161/CIRCULATIONAHA.106.618066. PMID 16769908.
  3. 3.0 3.1 Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L; et al. (2007). "Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment". Circulation. 116 (7): 745–54. doi:10.1161/CIRCULATIONAHA.106.686048. PMID 17664375.
  4. 4.0 4.1 Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC; et al. (2006). "Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents". Circulation. 113 (8): 1108–13. doi:10.1161/CIRCULATIONAHA.105.600155. PMID 16490815.
  5. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G; et al. (2005). "Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents". JAMA. 293 (17): 2126–30. doi:10.1001/jama.293.17.2126. PMID 15870416.

Template:WH Template:WS